Liver Cell Carcinoma
10 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma (NCT05366829) | Rutgers, The State University of New Jersey | 2022-07-25 |
| Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors (NCT05103631) | Baylor College of Medicine | 2021-06-17 |
| A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors (NCT04567615) | Bristol-Myers Squibb | 2021-02-04 |
| HepATocellular Cancer Hcv Therapy Study (NCT04546802) | Bayside Health | 2019-09-01 |
| A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma (NCT02460991) | Boston Scientific Corporation | 2015-11-01 |
| Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma (NCT00669136) | Lisa H. Butterfield, Ph.D. | 2009-06-01 |
Track Liver Cell Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.